Synergistic antinociceptive effects of concomitant NAAA and peripheral FAAH inhibition
Laboratory studyOther animalsWith URB937 (a peripheral FAAH inhibitor) and ARN19702 (a NAAA inhibitor), enzyme inhibitors that raise the body's own palmitoylethanolamide and anandamide; PEA itself was not given
This study tested palmitoylethanolamide together with URB937 (a peripheral FAAH inhibitor) and ARN19702 (a NAAA inhibitor), enzyme inhibitors that raise the body's own palmitoylethanolamide and anandamide; PEA itself was not given. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Male CD-1 mice in the formalin and carrageenan pain tests; numbers not stated in the abstract
- Dose used in the study
- Not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- Pain-related behaviour and paw inflammation in the formalin and carrageenan tests, with isobolographic analysis of the two inhibitors given together.
What the authors reported
Each inhibitor on its own reduced pain behaviour and paw inflammation. Given together, the combination produced greater-than-additive (synergistic) pain reduction in both models and additive anti-inflammatory effects in the carrageenan test.
Limits of this study
A mouse model; it cannot show effect in people or animals treated in practice. No palmitoylethanolamide was given; the study raised the body's own PEA and anandamide by blocking enzymes. Two authors hold patents on the NAAA and FAAH inhibitors used.
Source
PubMed 35932800 · doi:10.1016/j.expneurol.2022.114194
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.